Core Insights - Certara, Inc. reported a total revenue of $104.6 million for Q3 2025, reflecting a year-over-year growth of 10% [4][8] - The company has raised its profitability targets for 2025 and narrowed its revenue guidance to a range of $415 million to $420 million [3][15] - The CEO emphasized the launch of new software products, particularly CertaraIQ for QSP modeling, aimed at enhancing biosimulation technology in drug development [3] Financial Performance - Total revenue for Q3 2025 was $104.6 million, with software revenue at $43.8 million (22% growth) and services revenue at $60.8 million (3% growth) [4][5][8] - Total bookings reached $96.6 million, a 1% increase year-over-year, with software bookings growing by 17% [6][8] - Net income for Q3 2025 was $1.5 million, a significant improvement from a net loss of $1.4 million in Q3 2024, marking a 211% increase [12][8] Cost and Expenses - Total operating expenses for Q3 2025 were $61.9 million, up from $55.0 million in Q3 2024, primarily due to increased employee-related costs and stock-based compensation [10][8] - The cost of revenues was $39.7 million, an increase from $37.2 million in the same quarter last year [7][8] Adjusted Metrics - Adjusted EBITDA for Q3 2025 was $35.2 million, a 7% increase from $33.1 million in Q3 2024 [11][8] - Adjusted net income for Q3 2025 was $22.2 million, compared to $20.3 million in Q3 2024 [13][8] - Adjusted diluted earnings per share for Q3 2025 was $0.14, slightly up from $0.13 in Q3 2024 [13][8] Guidance and Outlook - The company expects full-year adjusted EBITDA margin to be approximately 32% and adjusted diluted earnings per share in the range of $0.45 to $0.47 [15] - Certara aims to continue investing in R&D and commercial efforts to ensure sustainable long-term growth [3]